Cumberland Pharmaceuticals CPIX Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Cumberland Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs?
- Cumberland Pharmaceuticals (CPIX) reported amortization expense related to capitalized debt issuance costs of $5.17K in Q1 2026.
- How has Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs decreased by 3.5% year-over-year, from $5.36K to $5.17K.
- What is the long-term trend for Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's amortization expense related to capitalized debt issuance costs has grown at a -9.2% compound annual growth rate (CAGR), from $34.05K to $23.19K.